Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.91% | 33.37% | 68.58% | 90.94% | 102.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.91% | 33.37% | 68.58% | 90.94% | 102.33% |
| Cost of Revenue | 13.89% | 56.69% | 106.88% | 135.33% | 150.87% |
| Gross Profit | -1.07% | 15.56% | 42.65% | 62.58% | 73.04% |
| SG&A Expenses | -42.55% | -39.68% | -7.57% | 15.06% | 45.35% |
| Depreciation & Amortization | 74.02% | 113.04% | 13.78% | -25.61% | -51.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.75% | -20.76% | 1.63% | 14.84% | 31.48% |
| Operating Income | 48.41% | 47.82% | 25.31% | 12.20% | -6.70% |
| Income Before Tax | 34.07% | 37.14% | 26.79% | 17.35% | 6.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.07% | 37.14% | 26.79% | 17.35% | 6.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.07% | 37.14% | 26.79% | 17.35% | 6.27% |
| EBIT | 48.41% | 47.82% | 25.31% | 12.20% | -6.70% |
| EBITDA | 48.67% | 51.54% | 26.29% | 10.02% | -14.70% |
| EPS Basic | 27.80% | 32.48% | 25.83% | 18.57% | 18.05% |
| Normalized Basic EPS | 27.75% | 32.65% | 16.92% | 8.25% | 6.99% |
| EPS Diluted | 27.80% | 32.48% | 25.83% | 18.57% | 18.05% |
| Normalized Diluted EPS | 27.75% | 32.65% | 16.92% | 8.25% | 6.99% |
| Average Basic Shares Outstanding | -3.39% | -2.51% | -1.56% | 1.27% | 15.04% |
| Average Diluted Shares Outstanding | -3.39% | -2.51% | -1.56% | 1.27% | 15.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |